PP01.17 Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)

The sotorasib EAP provided compassionate use of sotorasib, a first-in-class KRAS G12C inhibitor, prior to local regulatory approvals. An abstract presenting data on the safety and efficacy of sotorasib in patients with advanced KRAS p.G12C–mutated NSCLC from 2 global protocols under the EAP (Amgen study 20190436 [study-436] and 20190442 [study-442]) was submitted to ESMO 2022. Herein we provide focused analyses on the safety and efficacy of patients with previously treated or untreated brain metastases.